News

This week’s collection of the latest dermatologic studies covers an evaluation of the human stratum corneum with confocal Raman micro-spectroscopy, anti-mBP180 antibodies from mice, an updated review of alopecia areata comorbidities, and an ecchymotic patch related to chronic lymphocytic leukemia.

A grant from the National Institutes of Health will support continued research to develop products for soft tissue regeneration.

In subgroups based on age and bodyweight, treatment with secukinumab did not create new safety signals.

Researchers conducted systematic mapping of relevant DHI literature to determine the impact of these interventions on dermatologic care outcomes.

The guidance draft, once finalized, will enable the US FDA to have more oversight in the realm of cosmetic safety.

Clinically asymptomatic patients receiving alternative to conventional follow-up had a higher 3-year overall survival rate.

From bug bites to poison ivy, the skin can be exposed to a large spectrum of trouble while patients spend extended time outside.

In this week’s Pointers With Portela, the 208SkinDoc answers frequently asked questions about sunscreen use.

Clinicians can focus on patient care and leave human resources and bookkeeping to office staff.

Studies showed the various treatments improved symptoms, but more trials need to be done.

During the 25th World Congress of Dermatology, 40 rising stars and personalities were spotlighted for their contributions to the field.

This Psoriasis Awareness Month, test your knowledge of the condition. Click here to answer this week's poll.

More understanding of the physical, psychological, and economic burdens of hyperhidrosis is needed.

Few adverse events resulted from treatment with dupilumab in 64 weeks of observation.

Keep up with the latest headlines in dermatology from the past week, including cercarial dermatitis cases popping up across beaches in Connecticut, reports of Florida dermatologists encountering patients with leprosy, and more.

Leading atopic dermatitis experts delve into integrative approaches, prescription options, and strategies to encourage patients to stick with their treatment plan.

ICYMI, this week we had stories about laser treatments for port wine stain birthmarks, Abeona's briefing package filing for the BLA for its anticipated epidermolysis bullosa drug, using digital apps to detect skin cancers, and more.

The effects of the serum, Refine, can be seen in 6 to 12 months.

The fractional picosecond laser had a lower incidence of adverse events compared to fractional lasers.

The most common comorbidities identified included anxiety, dermatitis, hyperthyroidism, hyperlipidemia, and vitamin D deficiency.

While both cryotherapy and plasma exeresis are effective in clearing seborrheic keratosis lesions, researchers observed more statistically significant clearance in patients treated with plasma exeresis.

Clinicians can offer specials to patients, encouraging them to try new products or return for a refresh.

In this week’s Pointers With Portela, the 208SkinDoc reviews the benefits of oral minoxidil for hair loss.

"The analysis showed a statistically significant, positive effect of normal serum vitamin D levels on increasing ORR and PFS as a result of anti-PD‐1 immunotherapy in patients with locally advanced inoperable or metastatic melanoma,” according to a recent study.

Researchers found that use of personal protective equipment could be associated with skin problems; however, protective applications reduced these skin-related problems.

Supplements were based on amino acids and hydrolyzed collagen and were tested in patients with androgenic alopecia and chronic telogen effluvium.

The meta-analysis showed that patients treated with oral JAK inhibitors experienced more hair regrowth than those treated topically.

This week’s collection of the latest dermatologic studies covers defining biomarkers to predict treatment outcome based on immune checkpoint inhibitors, erythrodermic psoriasis in pediatric patients, surgical treatment of vulvar squamous cell carcinoma, and new and existing therapies for hand eczema.

The phase 1 study evaluated patient responses to cosibelimab in cases of locally advanced or metastatic cutaneous squamous cell carcinoma.

Hair loss affects self-esteem and feelings of well-being, but exciting treatments are on the horizon.